Log in

Cipher Pharmaceuticals Stock Price, News & Analysis (TSE:CPH)

C$1.25
+0.11 (+9.65 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
C$1.20
Now: C$1.25
C$1.25
50-Day Range
C$1.15
MA: C$1.37
C$1.63
52-Week Range
C$1.11
Now: C$1.25
C$3.06
Volume95,410 shs
Average Volume31,209 shs
Market CapitalizationC$33.67 million
P/E Ratio21.55
Dividend YieldN/A
BetaN/A
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-6025840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$21.96 million
Cash FlowC$0.35 per share
Book ValueC$1.01 per share

Profitability

Miscellaneous

Employees39
Market CapC$33.67 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive CPH News and Ratings via Email

Sign-up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.


Cipher Pharmaceuticals (TSE:CPH) Frequently Asked Questions

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH."

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (TSE:CPH) announced its quarterly earnings data on Friday, August, 9th. The company reported $0.07 EPS for the quarter, topping the Zacks' consensus estimate of $0.05 by $0.02. The company had revenue of $7.49 million for the quarter, compared to analysts' expectations of $7.30 million. View Cipher Pharmaceuticals' Earnings History.

When is Cipher Pharmaceuticals' next earnings date?

Cipher Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Cipher Pharmaceuticals.

What price target have analysts set for CPH?

2 Wall Street analysts have issued twelve-month price objectives for Cipher Pharmaceuticals' stock. Their forecasts range from C$1.50 to C$1.50. On average, they anticipate Cipher Pharmaceuticals' share price to reach C$1.50 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price. View Analyst Price Targets for Cipher Pharmaceuticals.

What is the consensus analysts' recommendation for Cipher Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cipher Pharmaceuticals.

Has Cipher Pharmaceuticals been receiving favorable news coverage?

Press coverage about CPH stock has been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cipher Pharmaceuticals earned a news impact score of -1.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

What other stocks do shareholders of Cipher Pharmaceuticals own?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 51)
  • Mr. Stephen L. Lemieux, CFO & Sec.
  • Mr. Chris Watters, VP of Corp. Devel.
  • Mr. Norman Evans, Consultant (Age 64)

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of CPH stock can currently be purchased for approximately C$1.25.

How big of a company is Cipher Pharmaceuticals?

Cipher Pharmaceuticals has a market capitalization of C$33.67 million and generates C$21.96 million in revenue each year. Cipher Pharmaceuticals employs 39 workers across the globe.View Additional Information About Cipher Pharmaceuticals.

What is Cipher Pharmaceuticals' official website?

The official website for Cipher Pharmaceuticals is http://www.cipherpharma.com/.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.


MarketBeat Community Rating for Cipher Pharmaceuticals (TSE CPH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel